JP2023542295A - Glp1ペプチド模倣薬を含む抗体薬物複合体及びその使用 - Google Patents

Glp1ペプチド模倣薬を含む抗体薬物複合体及びその使用 Download PDF

Info

Publication number
JP2023542295A
JP2023542295A JP2023516467A JP2023516467A JP2023542295A JP 2023542295 A JP2023542295 A JP 2023542295A JP 2023516467 A JP2023516467 A JP 2023516467A JP 2023516467 A JP2023516467 A JP 2023516467A JP 2023542295 A JP2023542295 A JP 2023542295A
Authority
JP
Japan
Prior art keywords
compound according
compound
linker
antibody
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023516467A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542295A5 (cg-RX-API-DMAC7.html
Inventor
ハン,エイミー
オカモト,ハルカ
オルソン,ウィリアム
Original Assignee
リジェネロン ファーマシューティカルズ,インク.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リジェネロン ファーマシューティカルズ,インク. filed Critical リジェネロン ファーマシューティカルズ,インク.
Publication of JP2023542295A publication Critical patent/JP2023542295A/ja
Publication of JP2023542295A5 publication Critical patent/JP2023542295A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023516467A 2020-09-14 2021-09-14 Glp1ペプチド模倣薬を含む抗体薬物複合体及びその使用 Pending JP2023542295A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063077983P 2020-09-14 2020-09-14
US63/077,983 2020-09-14
PCT/US2021/050337 WO2022056494A1 (en) 2020-09-14 2021-09-14 Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof

Publications (2)

Publication Number Publication Date
JP2023542295A true JP2023542295A (ja) 2023-10-06
JP2023542295A5 JP2023542295A5 (cg-RX-API-DMAC7.html) 2024-09-20

Family

ID=78080567

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023516467A Pending JP2023542295A (ja) 2020-09-14 2021-09-14 Glp1ペプチド模倣薬を含む抗体薬物複合体及びその使用

Country Status (12)

Country Link
US (2) US12280124B2 (cg-RX-API-DMAC7.html)
EP (1) EP4210767A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023542295A (cg-RX-API-DMAC7.html)
KR (1) KR20230070337A (cg-RX-API-DMAC7.html)
CN (1) CN116615251A (cg-RX-API-DMAC7.html)
AU (1) AU2021339892A1 (cg-RX-API-DMAC7.html)
CA (1) CA3191304A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023000678A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023004558A2 (cg-RX-API-DMAC7.html)
IL (1) IL301074A (cg-RX-API-DMAC7.html)
MX (1) MX2023002974A (cg-RX-API-DMAC7.html)
WO (1) WO2022056494A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023542295A (ja) 2020-09-14 2023-10-06 リジェネロン ファーマシューティカルズ,インク. Glp1ペプチド模倣薬を含む抗体薬物複合体及びその使用
CA3243669A1 (en) 2022-03-11 2023-09-14 Regeneron Pharmaceuticals, Inc. ANTI-GLP1R ANTIBODY-DRUG CONJUGATES INCLUDING GLP1 PEPTIDOMIMETS AND THEIR USES
CN119731206A (zh) * 2022-08-01 2025-03-28 先为达生物美国有限公司 抗glp-1r抗体及其用途
IL322391A (en) 2023-02-27 2025-09-01 Regeneron Pharma Liquid-phase peptide-supported synthesis of peptides and peptide-like molecules
CN122295135A (zh) 2023-11-03 2026-06-26 瑞泽恩制药公司 作为glp1r激动剂的肽酸及其抗体-药物缀合物
IL330385A (en) * 2023-12-29 2026-08-01 Jiangsu Hengrui Pharmaceuticals Co Ltd Antibody-polypeptide conjugate and its pharmaceutical use
WO2026024847A2 (en) * 2024-07-23 2026-01-29 Baylor University Chemical probes for microbial mucin degraders in the gut microbiome

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011048614A2 (en) * 2009-10-22 2011-04-28 Cadila Healthcare Limited Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist
JP5270687B2 (ja) * 2007-12-11 2013-08-21 カディラ ヘルスケア リミティド グルカゴンアンタゴニスト活性及びglp−1アゴニスト活性を有するペプチド模倣体
GB2551945A (en) * 2015-12-18 2018-01-10 Heptares Therapeutics Ltd Novel GLP-1 receptor agonist peptides
US20180311372A1 (en) * 2017-01-17 2018-11-01 Amgen Inc. Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
US20060275288A1 (en) * 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
US7985557B2 (en) 2007-05-23 2011-07-26 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
UA108598C2 (xx) 2008-04-30 2015-05-25 Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
ES2560807T3 (es) 2008-07-21 2016-02-22 Polytherics Limited Nuevos reactivos y procedimiento de conjugación de moléculas biológicas
FR2937972B1 (fr) 2008-11-04 2013-03-29 Galderma Res & Dev Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
KR101000067B1 (ko) 2008-12-30 2010-12-10 엘지전자 주식회사 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법
DK2889624T3 (en) 2009-08-10 2018-12-10 Ucl Business Plc Reversible covalent bonding of functional molecules
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
PT2528625E (pt) 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
EP2601298B1 (en) 2010-08-02 2016-11-30 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising vl domains
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
DK2714685T3 (en) 2011-05-27 2017-01-09 Ambrx Inc FORMATIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID BOUND dolastatin
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
JP6166728B2 (ja) 2011-10-14 2017-07-19 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体
AU2012322934B2 (en) 2011-10-14 2016-09-08 Medimmune Limited Pyrrolobenzodiazepines
CA2850375C (en) 2011-10-14 2019-07-02 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
BR112014013526A8 (pt) 2011-12-05 2017-06-13 Igenica Biotherapeutics Inc conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
HRP20180268T4 (hr) 2012-10-23 2026-03-27 Synaffix B.V. Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁(杭州)生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
WO2015187596A2 (en) 2014-06-02 2015-12-10 Regeneron Pharmaceuticals, Inc. Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses
US9911931B2 (en) 2014-06-26 2018-03-06 Universal Display Corporation Organic electroluminescent materials and devices
MX390630B (es) 2016-01-25 2025-03-21 Regeneron Pharma Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
EP3419670A2 (en) * 2016-02-26 2019-01-02 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
KR20250008984A (ko) * 2017-05-18 2025-01-16 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
MX2022014090A (es) 2020-05-12 2023-02-27 Regeneron Pharma Anticuerpos antagonistas anti-glp1r y metodos de uso de los mismos.
JP2023542295A (ja) 2020-09-14 2023-10-06 リジェネロン ファーマシューティカルズ,インク. Glp1ペプチド模倣薬を含む抗体薬物複合体及びその使用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5270687B2 (ja) * 2007-12-11 2013-08-21 カディラ ヘルスケア リミティド グルカゴンアンタゴニスト活性及びglp−1アゴニスト活性を有するペプチド模倣体
WO2011048614A2 (en) * 2009-10-22 2011-04-28 Cadila Healthcare Limited Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist
GB2551945A (en) * 2015-12-18 2018-01-10 Heptares Therapeutics Ltd Novel GLP-1 receptor agonist peptides
US20180311372A1 (en) * 2017-01-17 2018-11-01 Amgen Inc. Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)

Also Published As

Publication number Publication date
WO2022056494A1 (en) 2022-03-17
US12280124B2 (en) 2025-04-22
US20220096648A1 (en) 2022-03-31
AU2021339892A9 (en) 2024-02-08
MX2023002974A (es) 2023-05-25
CL2023000678A1 (es) 2023-10-20
CA3191304A1 (en) 2022-03-17
EP4210767A1 (en) 2023-07-19
CO2023004558A2 (es) 2023-04-27
AU2021339892A1 (en) 2023-04-27
KR20230070337A (ko) 2023-05-22
US20250161476A1 (en) 2025-05-22
CL2025002511A1 (es) 2025-10-03
IL301074A (en) 2023-05-01
CN116615251A (zh) 2023-08-18

Similar Documents

Publication Publication Date Title
US12280124B2 (en) Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof
US20220362396A1 (en) Amino-pyrazinecarboxamide compounds, conjugates, and uses thereof
US20230330254A1 (en) Anti-glp1r antibody-tethered drug conjugates comprising glp1 peptidomimetics and uses thereof
AU2015280351B2 (en) Fatty acids and their use in conjugation to biomolecules
CA3098453A1 (en) Anti-msr1 antibodies and methods of use thereof
CA3041046A1 (en) Immunoglobulins and uses thereof
TW202102225A (zh) 抗her2抗體-吡咯并苯二氮呯衍生物結合物
JP2024531480A (ja) ステロイド化合物及びそのコンジュゲート
KR20240000510A (ko) 소르틸린 활성 조절제
WO2023221975A1 (zh) 包含蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途
JP2013503626A (ja) グルカゴン受容体に対する抗体と、それらの使用
JP2022095624A (ja) 代謝障害の治療に有用な化合物
AU2024372425A1 (en) Peptide acids as a glp1r agonist and antibody-drug conjugates thereof
JP2025508927A (ja) ソルチリン依存性疾患を治療するためのアミノ酸ベースのカルバメート及び/又は尿素
EP3455221B1 (en) Dimeric compounds
WO2025085489A1 (en) Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof
EA051876B1 (ru) Конъюгаты антитело-лекарственное средство, содержащие пептидомиметики glp1, и их применения
IL325400A (en) Anti-human CACNG1 antibody-drug conjugates and their uses
WO2025247309A1 (zh) 融合蛋白分子及其应用
JP2026508282A (ja) ペプチドおよびペプチド模倣体の液相ペプチド支持体合成
EA050796B1 (ru) Иммуноглобулины и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240911

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260522

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260803